INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Imperial College London
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de Imperial College London (89)
2024
-
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12
-
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
eClinicalMedicine, Vol. 69
2023
-
A Human Hereditary Cardiomyopathy Shares a Genetic Substrate With Bicuspid Aortic Valve
Circulation, Vol. 147, Núm. 1, pp. 47-65
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
2022
-
Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study
European Urology Focus, Vol. 8, Núm. 6, pp. 1673-1682
-
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
American Journal of Hematology
-
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study
European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study
Liver International, Vol. 42, Núm. 8, pp. 1891-1901
2021
-
Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
Translational Psychiatry, Vol. 11, Núm. 1
-
Assessment tool of bipolar disorder for primary health care: The saebd
International Journal of Environmental Research and Public Health, Vol. 18, Núm. 16
-
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
BMC Infectious Diseases, Vol. 21, Núm. 1
-
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Leukemia, Vol. 35, Núm. 10, pp. 2885-2894
-
Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function (Translational Psychiatry, (2021), 11, 1, (579), 10.1038/s41398-021-01705-z)
Translational Psychiatry
-
Developing the surgical technique reporting checklist and standards: a study protocol
Gland Surgery, Vol. 10, Núm. 8, pp. 2591-2599
-
Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis
The Lancet Psychiatry, Vol. 8, Núm. 7, pp. 589-598
-
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718
-
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Journal of Hematology and Oncology